GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (BUE:LLY) » Definitions » Institutional Ownership

Eli Lilly and Co (BUE:LLY) Institutional Ownership : 7.59% (As of Apr. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Eli Lilly and Co Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Eli Lilly and Co's institutional ownership is 7.59%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Eli Lilly and Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Eli Lilly and Co's Float Percentage Of Total Shares Outstanding is 0.00%.


Eli Lilly and Co Institutional Ownership Historical Data

The historical data trend for Eli Lilly and Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Institutional Ownership Chart

Eli Lilly and Co Historical Data

The historical data trend for Eli Lilly and Co can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 7.60 7.60 7.60 7.60 7.60 7.60 7.60 7.60 7.59 7.59

Eli Lilly and Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Eli Lilly and Co (BUE:LLY) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.